By Connor Hart
Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases.
Terms of the deal weren't disclosed.
Aurion will operate as a separate company from Alcon, whose products include contact lenses and eye drops. The deal will also see Arnaud Lacoste, who most recently served as Aurion's chief scientific officer, assume the CEO role at Aurion, Swiss-based Alcon said.
Under the agreement, Aurion will have access to Alcon's broader research and development, regulatory, medical ophthalmic and commercial capabilities, the latter company said. These supports will aid Aurion's development of AURN001, a treatment for corneal edema, or swelling of the cornea, which can occur as a secondary effect of corneal endothelial disease.
Aurion previously received a breakthrough therapy designation, as well as a regenerative medicine advanced therapy designation, from the Food and Drug Administration for AURN001. The treatment has not yet been approved by the agency.
"We look forward to leveraging Alcon's global resources and commercial expertise as we initiate our U.S. Phase 3 trials later this year," Lacoste said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
March 26, 2025 17:07 ET (21:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。